Esra TANYEL, Aydın DEVECİ, Mustafa KURÇALOĞLU, Sertaç KETENCİ, Fuat GÜLDOĞUŞ, Fatih ÖZKAN, Heval Can BİLEK, Sümeyra Nur ERBAŞ

COVID-19 hastalarında ağrı değerlendirmesi

Amaç: Yeni bir tip koronavirüs salgını Çin’de ortaya çıktı ve pandemik oldu. Dünya Sağlık Örgütü (DSÖ) bu hastalığın resmî adını ‘COVID-19’ olarak ilan etti. Bu çalışmanın ana amacı COVID-19 hastalarında ağrıyı değerlendirmektir. Gereç ve Yöntem: 2020 yılının Mayıs ve Eylül ayları arasında muhtemel veya kesin COVID-19 tanısıyla enfeksiyon hastalıkları servisinde takip edilmiş olan toplam 178 hasta çalışmaya dahil edildi. Kısa Ağrı Envanteri’nin (BPI) Türkçe versiyonu uygulandı. Demografik özellikler, ağrının sıklığı, lokasyonu, şiddeti ve analjeziklere yanıtı analiz edildi. Bulgular: Hastaların doksan birinde (%51.1) ağrı şikayeti vardı ve ortalama ağrı skoru (OAS) 10 uzerinden 2,28±2,81’di. Ağrısı olan hastalardan elli dokuzu (%56.0) ağrı kesiciye ihtiyac duydu ve kırk birinde (%80.3) basit ağrı kesicilerle yuzde elliden daha fazla ağrı azalması saptandı. Yeterli ağrı palyasyonu sağlanamayan on sekiz hastanın on ikisinin ağrı kesicilerini duzenli olarak almak yerine ağrı oldukca almış oldukları gozlendi. Muhtemel ve kesin vakaların ağrı frekansı, şiddeti ve hastanede kalış suresi benzerdi. Sonuç: Sonuçlarımıza göre COVID-19 hastalarında ağrının baş edilmesi zor bir semptom olmadığı ve hafif-orta klinik şiddet- teki hastalarda kolaylıkla tedavi edilebildiği kanaatine vardık. Sonuçlarımız ağrı ve hastalığın klinik seyri arasında bir bağlantı kurmak için yeterli değildi. Ağrı değerlendirmesi için yoğun bakım hastalarını içeren başka çalışmalara ihtiyaç vardır.

Evaluation of pain in patients with COVID-19

Objectives: A new type of coronavirus outbreak has emerged in China and caused a pandemic. World Health Organization (WHO) announced the official name of this disease ‘COVID-19’. The main purpose of this study is to evaluate pain in COVID-19 patients. Methods: Patients who were followed in the ward of an infectious diseases department because of possible or confirmed COVID-19 between May and September of 2020 were included in the study. The Turkish version of the Brief Pain Inventory (BPI) was applied. Demographic features, frequency, location, the intensity of pain, and response to analgesics were analyzed. Results: A total of 178 participants were included in the study. Ninety-one (51.1%) of patients had pain complaints and the mean pain score (MPS) was 2.28±2.81 over 10. Fifty-nine (56.0%) of participants with pain required analgesic therapy and 41 (80.3%) of them showed ≥50% pain relief with simple analgesics. Twelve of the remaining 18 who did not get enough pain relief with simple analgesic were taking their analgesics pro re nata (PRN) rather than around the clock (ATC). Pain frequency and intensity and mean hospitalization duration (MHD) were similar between confirmed and possible cases. Conclusion: Regarding the results, we conclude that pain is not one of the challenging symptoms and easily manageable in patients with a mild-moderate intensity of COVID-19. Our results were not enough to make a correlation between pain and the clinical course of the disease. Further studies are required for the evaluation of pain including patients in intensive care units.

PDF

___

1. Baj J, Karakula-Juchnowicz H, Teresinski G, Buszewicz G, Ciesielka M, Sitarz E, et al. COVID-19: Specific and non- specific clinical manifestations and symptoms: the current state of knowledge. J Clin Med 2020;9(6):1753.
2. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(6):577–583.
3. Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med 2020;383(18):1757–66.
4. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clini- cal characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect 2020;80(6):656–65.
5. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091.
6. Li JY, You Z, Wang Q, Zhou ZJ, Qiu Y, Luo R, et al. The epi- demic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect 2020;22(2):80–5.
7. Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, She- hata AA. The COVID-19 Pandemic: A Comprehensive Re- view of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control. J Clin Med 2020;9(4):1225.
8. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis 2020;94:154–5.
9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506.
10. Borges do Nascimento IJ, Cacic N, Abdulazeem HM, von Groote TC, Jayarajah U, Weerasekara I, et al. Novel coro- navirus infection (COVID-19) in humans: a scoping review and meta-analysis. J Clin Med 2020;9(4):941.
11. Zhang X, Cai H, Hu J, Lian J, Gu J, Zhang S, et al. Epide - miological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis 2020;94:81–7.
12. Bolay H, Gül A, Baykan B. COVID-19 is a real headache! Headache 2020;60(7):1415–21
13. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain 2004;5(2):133–7.
14. Cleeland CS. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, editors. Advances in Pain Re- search and Therapy. Vol. 12. Issues in Pain Measurement. New York: Raven Press; 1989. p. 391–403.
15. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 1994;23(2):129– 38.
16. Dicle A, Karayurt O, Dirimese E. Validation of the Turkish version of the Brief Pain Inventory in surgery patients. Pain Manag Nurs 2009;10(2):107–113.e2.
17. Yildirim Y, Parlar Kılıç S, Eyigor S, Eyigor C, Yildirim Y, Kara- man E, et al. Validity and reliability of Turkish version of the Brief Pain Inventory-Short Form for patients with chronic nonmalignant pain. Agri 2019;31(4):195–201. (English)
18. Togay A, Yılmaz N. Laboratory Diagnosis of SARS-CoV-2. Tepecik Egit ve Arast Hast Dergisi 2020;30(Ek sayı):70–5. (Turkish)
19. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA 2020;323(18):1843–4.
20. Fang FC, Naccache SN, Greninger AL. The Laboratory Di - agnosis of Coronavirus Disease 2019- Frequently Asked Questions. Clin Infect Dis 2020;71(11):2996–3001.
21. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ 2020;369:m1443.
22. Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dy- namics in mild and severe cases of COVID-19. Lancet Infect Dis 2020;20(6):656–57.
23. Bartley EJ, Fillingim RB. Sex differences in pain: a brief re- view of clinical and experimental findings. Br J Anaesth 2013;111(1):52–8.
24. Gerdle B, Björk J, Cöster L, Henriksson K, Henriksson C, Bengtsson A. Prevalence of widespread pain and associa - tions with work status: a population study. BMC Musculo- skelet Disord 2008;9:102.
25. Mogil JS. Sex differences in pain and pain inhibition: mul - tiple explanations of a controversial phenomenon. Nat Rev Neurosci 2012;13(12):859–66.
26. Craft RM. Modulation of pain by estrogens. Pain 2007;132(Suppl 1):S3–12.
27. Smith YR, Stohler CS, Nichols TE, Bueller JA, Koeppe RA, Zubieta JK. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci 2006;26(21):5777–85.
28. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL 3rd. Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain 2009;10(5):447– 85.
29. Racine M, Tousignant-Laflamme Y, Kloda LA, Dion D, Du- puis G, Choinière M. A systematic literature review of 10 years of research on sex/gender and pain perception - part 2: do biopsychosocial factors alter pain sensitivity differ- ently in women and men? Pain 2012;153(3):619–35.
30. Unruh AM, Ritchie J, Merskey H. Does gender affect ap - praisal of pain and pain coping strategies? Clin J Pain 1999;15(1):31–40
31. Sullivan MJ, Thorn B, Haythornthwaite JA, Keefe F, Martin M, Bradley LA, Lefebvre JC. Theoretical perspectives on the relation between catastrophizing and pain. Clin J Pain 2001;17(1):52–64.
32. Bandura A. Self-efficacy: toward a unifying theory of be- havioral change. Psychol Rev 1977 84(2):191–215.
33. Keefe FJ, Brown GK, Wallston KA, Caldwell DS. Coping with rheumatoid arthritis pain: catastrophizing as a maladap - tive strategy. Pain 1989;37(1):51–6.
34. Forsythe LP, Thorn B, Day M, Shelby G. Race and sex dif- ferences in primary appraisals, catastrophizing, and ex- perimental pain outcomes. J Pain 2011;12(5):563–72. DOI: 10.1016/j.jpain.2010.11.003
35. Somers TJ, Kurakula PC, Criscione-Schreiber L, Keefe FJ, Clowse ME. Self-efficacy and pain catastrophizing in sys- temic lupus erythematosus: relationship to pain, stiff - ness, fatigue, and psychological distress. Arthritis Care Res (Hoboken) 2012;64:1334–40.
36. Jackson T, Iezzi T, Gunderson J, Nagasaka T, Fritch A. Gen- der differences in pain perception: the mediating role of self-efficacy beliefs. Sex Roles 2002;47(11/12):561–8.
37. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical charac- teristics of 3062 COVID-19 patients: A meta-analysis. J Med Virol 2020;92(10):1902–14.
38. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recog- nition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Corona- virus. J Virol 2020;94(7):e00127–20.
39. Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibu- profen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect 2020;26(9):1259.e5–7.